Peptide Initiative

Peptides · Peptide comparison

Nisin vs Thymosin Alpha-1

FDA GRAS-approved lantibiotic (34 amino acids) produced by Lactococcus lactis with a dual antimicrobial mechanism — binds lipid II to block cell wall synthesis AND forms 2 nm transmembrane pores for rapid bacterial killing at MIC 0.5-4 μg/mL against gram-positive pathogens including MRSA and Listeria monocytogenes — the only antimicrobial peptide with over 50 years of documented safe human consumption

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeNisin10–50 mcg/mLThymosin Alpha-11.6–1.6 mg
FrequencyNisinOnce dailyThymosin Alpha-1Twice weekly
AdministrationNisinOral (food-grade preservative, GRAS)Thymosin Alpha-1Subcutaneous injection
Cycle lengthNisinOngoing/indefiniteThymosin Alpha-18-12 weeks
Onset speedNisinRapid (hours to days)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelNisinStrong human trials (Phase 3 or FDA approved)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Immune

Nisin9%
Thymosin Alpha-1No recorded rating

Healing & Recovery

Nisin7%
Thymosin Alpha-1No recorded rating

Anti-Aging

Nisin5%
Thymosin Alpha-1No recorded rating

Immune Activation

NisinNo recorded rating
Thymosin Alpha-195%

Infection Fighting

NisinNo recorded rating
Thymosin Alpha-192%

Immune Balance

NisinNo recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Nisin

Molecular formula
C143H230N42O37S7
Molecular weight
3,354.12 Da
Half-life
Rapidly degraded in GI tract by digestive proteases; stable for hours to days in food matrices at acidic pH; lanthionine ring structures resist most environmental proteases; thermostable (survives pasteurization)
Bioavailability
Degraded by pancreatic proteases in GI tract (does not affect gut microbiome at dietary levels); topical application achieves effective local concentrations; optimal activity at pH 2-6; lanthionine bridges provide significant protease resistance compared to linear peptides
CAS number
1414-45-5

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Nisin

Topical

  • 10-50 mcg/mL applied to the affected areaOnce or twice daily · Research protocol-dependent (typically 1-4 weeks)Topical antimicrobial concentration range used in wound-care and infection-control research [5]. Investigational; not an approved human therapeutic route.

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Nisin

Food preservation as a natural antimicrobial alternative to chemical preservatives
Nisin is particularly well-suited for individuals focused on food preservation as a natural antimicrobial alternative to chemical preservatives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research into novel antimicrobial therapeutics based on lantibiotic scaffolds
Nisin is particularly well-suited for individuals focused on research into novel antimicrobial therapeutics based on lantibiotic scaffolds. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-Listeria and anti-Clostridium strategies in food safety and clinical settings
Nisin is particularly well-suited for individuals focused on anti-listeria and anti-clostridium strategies in food safety and clinical settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and dental applications
Nisin is particularly well-suited for individuals focused on development of antimicrobial wound dressings and dental applications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Nisin

Common

  • No significant effects at dietary levels
  • Mild GI discomfort at research doses
  • Local irritation (topical use)

Uncommon

  • Milk protein allergic reaction
  • Gram-negative overgrowth

Serious

  • No documented serious adverse effects

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Nisin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not an FDA-approved drug. Nisin preparation is affirmed as GRAS (21 CFR 184.1538, 1988) only as a food antimicrobial, for example to inhibit Clostridium botulinum in pasteurized cheese spreads; therapeutic uses are investigational.
Safety overview
Nisin holds FDA GRAS status since 1988 with over 50 years of documented safe human consumption, making it the only antimicrobial peptide with this comprehensive long-term safety record. Oral LD50 of 174 mg/kg in mice (comparable to table salt) demonstrates extraordinary safety margin. Acceptable daily intake established at 0.13 mg/kg body weight with no reported serious adverse events at this or higher levels. Primary risk is milk protein contamination during production, requiring screening for lactose-intolerant or milk-allergic individuals.

Contraindications

  • Known hypersensitivity to nisin or Lactococcus lactis-derived products
  • Milk protein allergy — nisin production involves dairy-associated bacteria and preparations may contain trace milk proteins
  • Pregnancy and breastfeeding at therapeutic (non-dietary) doses — standard dietary exposure through preserved foods is considered safe
  • Active inflammatory bowel disease — potential for local irritation at high oral concentrations exceeding normal dietary levels

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Nisin

Choose Nisin if…

  • Food preservation as a natural antimicrobial alternative to chemical preservatives
  • Research into novel antimicrobial therapeutics based on lantibiotic scaffolds
  • Anti-Listeria and anti-Clostridium strategies in food safety and clinical settings
  • Development of antimicrobial wound dressings and dental applications

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support